Russian Academy of Sciences spinout PM&HM has signed up a second government-owned vehicle to help commercialise its digitally-enabled inhaler for tuberculosis, cancer and HIV.

Personal Medication and Health Management (PM&HM), a Russia-based connected inhaler system developer based on Russian Academy of Sciences research, has received 305m rubles ($4.6m) of funding, according to East-West Digital News.
The capital came from the National Technology Initiative Support Fund, an investment vehicle established by Russian government-owned fund-of-funds RVC.
PM&HM is developing a digitally-enabled inhaler for tuberculosis, cancer and HIV that comes with a fingerprint identifier, removable medication cartridge and telemedicine communication capabilities to help clinicians monitor patients’ dosing schedules.
The device pushes information through the cloud to a smartphone app which alerts the patient to scheduled dosages and provides a contact point with physicians. Clinicians can use the software to accurately calculate regimens and look for counterfeit medications.
PM&HM’s inhaler is expected to help healthcare providers restrict the quantities of powerful drugs needed to treat its target diseases. It aims to have the system installed in 30% of Russia’s state hospitals and medical establishments by 2025, at a price point of between $75 and $300.
The company reportedly last raised $3.4m in a 2017 round from another Russian public investment vehicle, the Internet Initiatives Development Fund, in exchange for a 35% stake.
PM&HM was also supported by Russia’s National Technology Initiative, a government-sponsored program which aims to drive technological innovation in the country leading up to 2035.
Feature image courtesy of PM&HM